Citations

Clear

80 citation(s) found for "Pignolo, RJ".

Druggable targets, clinical trial design and proposed pharmacological management in fibrodysplasia ossificans progressiva
Pignolo, Robert J. , Kaplan, Frederick S.

Mayo Clinic

Expert Opinion on Orphan Drugs | April 4, 2020 | Volume: 8 | Issue: 4 | Pages: 101-109

10.1080/21678707.2020.1751122 Get It

Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss
Chandra, Abhishek , Lagnado, Anthony B. , Farr, Joshua N. , Monroe, David G. , Hachfeld, Christine, Kirkland, James L. , Khosla, Sundeep , Passos, João F. , Pignolo, Robert J. , Park, Sean, Khosla, Sundeep , Pignolo, Robert J , Passos, João F , Monroe, David G , Farr, Joshua N , Chandra, Abhishek , Park, Sean S. , Tchkonia, Tamar

Mayo Clinic

Journal of Bone and Mineral Research | February 5, 2020 | Volume: 35 | Issue: 6 | Pages: 1119-1131

10.1002/jbmr.3978 | PMID 32023351 Get It

ABSTRACT Clinical radiotherapy treats life-threatening cancers, but the radiation often affects neighboring normal tissues including bone. Acute effects of ionizing radiation include oxidative stress, DNA damage, and cellular apoptosis. We show in this study that a large proportion of bone marrow cells, osteoblasts, and matrix-embedded osteocytes recover from these insults only to attain a senescent profile. Bone analyses of senescence-associated genes, senescence-associated beta-galactosidase (SA-β-gal) activity, and presence of telomere dysfunction-induced foci (TIF) at 1, 7, 14, 21, and 42 days post–focal radiation treatment (FRT) in C57BL/6 male mice confirmed the development of senescent cells and the senescence-associated secretory phenotype (SASP). Accumulation of senescent cells and SASP markers were correlated with a significant reduction in bone architecture at 42 days post-FRT. To test if senolytic drugs, which clear senescent cells, alleviate FRT-related bone damage, we administered the senolytic agents, dasatinib (D), quercetin (Q), fisetin (F), and a cocktail of D and Q (D+Q). We found moderate alleviation of radiation-induced bone damage with D and Q as stand-alone compounds, but no such improvement was seen with F. However, the senolytic cocktail of D+Q reduced senescent cell burden as assessed by TIF+ osteoblasts and osteocytes, markers of senescence (p16 Ink4a and p21), and key SASP factors, resulting in significant recovery in the bone architecture of radiated femurs. In summary, this study provides proof of concept that senescent cells play a role in radiotherapy-associated bone damage, and that reduction in senescent cell burden by senolytic agents is a potential therapeutic option for alleviating radiotherapy-related bone deterioration. © 2020 American Society for Bone and Mineral Research.
Creating the Next Generation of Translational Geroscientists
Newman, John C., Sokoloski, Julie L., Niedernhofer, Laura J. , Reed, May J. , Wei, Jeanne, Austad, Steven N. , Barzilai, Nir , Cohen, Harvey Jay, Kuchel, George A. , Kirkland, James L. , Pignolo, Robert J. , Niedernhofer, Laura J , Kuchel, George A , Newman, John C., Robbins, Paul D.

Mayo Clinic

Journal of the American Geriatrics Society | July 9, 2019 | Volume: 67 | Issue: 9 | Pages: 1934-1939

10.1111/jgs.16055 | PMID 31287934 Get It

Advances in understanding fundamental processes of aging have led to a variety of investigational therapies to delay or prevent age‐related diseases and conditions. These geroscience therapeutics hold the promise of revolutionizing medical care of older adults by treating the complex syndromes of aging and preserving health and independence. A crucial bottleneck is the study of geroscience therapeutics in early‐stage, first‐in‐human, or proof‐of‐concept clinical trials. There is a limited pool of clinical investigators with the combination of knowledge and skills at the interface of clinical research, care of older adults, and aging biology needed to successfully design, fund, and implement geroscience trials. Current training pipelines are insufficient to meet the need. The sixth retreat of the National Institute on Aging R24 Geroscience Network brought together basic scientists, gerontologists, clinicians, and clinical researchers from the United States and Europe to discuss how to identify, recruit, and train investigators who can perform early‐stage clinical trials in geroscience. We present herein the group's consensus on necessary subject domains and competencies, identification of candidate learners, credentialing learners, and the efficient and rapid implementation of training programs. Foundations and funding agencies have crucial roles to play in catalyzing the development of these programs. Geriatrician investigators are indispensable but cannot meet the need alone. Translational geroscience training programs can create a cadre of groundbreaking investigators from a variety of backgrounds and foster institutional cultures supportive of multidisciplinary translational aging research to turn innovative ideas into transformative therapeutics that can improve the health and independence of older adults. J Am Geriatr Soc 67:1934–1939, 2019
Molecular characterization of known and novel ACVR1 variants in phenotypes of aberrant ossification
Gupta, Aditi , Zimmermann, Michael T. , Sigafoos, Ashley N. , Macklin, Sarah , Pignolo, Robert J. , Klee, Eric W. , Macklin, Sarah K, Urrutia, Raul A, Zimmermann, Michael T , Wang, Haitao , Broski, Stephen M. , Urrutia, Raúl , Clark, Karl J. , Atwal, Paldeep S

Mayo Clinic

American Journal of Medical Genetics Part A | June 26, 2019 | Volume: 179 | Issue: 9 | Pages: 1764-1777

10.1002/ajmg.a.61274 | PMID 31240838 Get It

AbstractDiffuse idiopathic skeletal hyperostosis (DISH) is a disorder principally characterized by calcification and ossification of spinal ligaments and entheses. Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disabling disorder characterized by progressive ossification of skeletal muscle, fascia, tendons, and ligaments. These conditions manifest phenotypic overlap in the ossification of tendons and ligaments. We describe herein a patient with DISH, exhibiting heterotopic ossification of the posterior longitudinal ligament where clinical whole exome sequencing identified a variant within ACVR1, a gene implicated in FOP. This variant, p.K400E, is a novel variant, not identified previously, and occurs in a highly conserved region across orthologs. We used sequence‐based predicative algorithms, molecular modeling, and molecular dynamics simulations, to test the potential for p.K400E to alter the structure and dynamics of ACVR1. We applied the same modeling and simulation methods to established FOP variants, to identify the detailed effects that they have on the ACVR1 protein, as well as to act as positive controls against which the effects of p.K400E could be evaluated. Our in silico molecular analyses support p.K400E as altering the behavior of ACVR1. In addition, functional testing to measure the effect of this variant on BMP‐pSMAD 1/5/8 target genes was carried out which revealed this variant to cause increased ID1 and Msx2 expression compared with the wild‐type receptor. This analysis supports the potential for the variant of uncertain significance to contribute to the patient's phenotype.
Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)
Hsiao, Edward C. , Rocco, Maja Di , Cali, Amanda, Zasloff, Michael , Mukaddam, Mona Al , Pignolo, Robert J. , Grunwald, Zvi, Netelenbos, Coen , Keen, Richard , Brown, Matthew A. , Cunto, Carmen De , Delai, Patricia , Haga, Nobuhiko , Morhart, Rolf, Scott, Christiaan , Zhang, Keqin , Diecidue, Robert J. , Friedman, Clive, Kaplan, Frederick S. , Eekhoff, Elisabeth M. W. , Hsiao, Edward C , Baujat, Geneviève , Cho, Tae‐Joon , Brown, Matthew , Kaplan, Frederick S

Mayo Clinic

British Journal of Clinical Pharmacology | October 5, 2018 | Volume: 85 | Issue: 6 | Pages: 1199-1207

10.1111/bcp.13777 | PMID 30281842 Get It

Clinical trials for orphan diseases are critical for developing effective therapies. One such condition, fibrodysplasia ossificans progressiva (FOP; MIM#135100), is characterized by progressive heterotopic ossification (HO) that leads to severe disability. Individuals with FOP are extremely sensitive to even minor traumatic events. There has been substantial recent interest in clinical trials for novel and urgently‐needed treatments for FOP. The International Clinical Council on FOP (ICC) was established in 2016 to provide consolidated and coordinated advice on the best practices for clinical care and clinical research for individuals who suffer from FOP. The Clinical Trials Committee of the ICC developed a focused list of key considerations that encompass the specific and unique needs of the FOP community – considerations that are endorsed by the entire ICC. These considerations complement established protocols for developing and executing robust clinical trials by providing a foundation for helping to ensure the safety of subjects with FOP in clinical research trials.
Serum vitamin C levels modulate the lifespan and endoplasmic reticulum stress response pathways in mice synthesizing a nonfunctional mutant WRN protein
Aumailley, Lucie , Dubois, Marie Julie, Brennan, Tracy A., Garand, Chantal , Paquet, Éric R. , Pignolo, Robert J. , Marette, André , Lebel, Michel

Mayo Clinic

The FASEB Journal | February 8, 2018 | Volume: 32 | Issue: 7 | Pages: 3623-3640

10.1096/fj.201701176r | PMID 29452565 Get It

Werner syndrome (WS) is a premature aging disorder caused by mutations in a RecQ‐family DNA helicase (WRN). Mice lacking part of the helicase domain of the WRN ortholog exhibit several phenotypic features of WS. In this study, we generated a Wrn mutant line that, like humans, relies entirely on dietary sources of vitamin C (ascorbate) to survive, by crossing them to mice that lack the gulonolactone oxidase enzyme required for ascorbate synthesis. In the presence of 0.01% ascorbate (w/v) in drinking water, double‐mutant mice exhibited a severe reduction in lifespan, small size, sterility, osteopenia, and metabolic profiles different from wild‐type (WT) mice. Although increasing the dose of ascorbate to 0.4% improved dramatically the phenotypes of double‐mutant mice, the metabolic and cytokine profiles were different from age‐matched WT mice. Finally, double‐mutant mice treated with 0.01% ascorbate revealed a permanent activation of all the 3 branches of the ER stress response pathways due to a severe chronic oxidative stress in the ER compartment. In addition, markers associated with the ubiquitinproteasome‐dependent ER‐associated degradation pathway were increased. Augmenting the dose of ascorbate reversed the activation of this pathway to WT levels rendering this pathway a potential therapeutic target in WS.—Aumailley, L., Dubois, M. J., Brennan, T. A., Garand, C., Paquet, E. R., Pignolo, R. J., Marette, A., Lebel, M. Serum vitamin C levels modulate the lifespan and endoplasmic reticulum stress response pathways in mice synthesizing a nonfunctional mutant WRN protein. FASEB J. 32, 3623–3640 (2018). www.fasebj.org
Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis
Chandra, Abhishek , Wang, Luqiang, Young, Tiffany, Zhong, Leilei , Tseng, Wei‐Ju , Levine, Michael A. , Cengel, Keith A. , Pignolo, Robert J. , Qin, Ling , Liu, X. Sherry , Zhang, Yejia , Levine, M A , Chandra, Abhishek

Mayo Clinic

The FASEB Journal | August 31, 2017 | Volume: 32 | Issue: 1 | Pages: 52-62

10.1096/fj.201700375r | PMID 28860152 Get It

Bone atrophy and its related fragility fractures are frequent, late side effects of radiotherapy in cancer survivors and have a detrimental impact on their quality of life. In another study, we showed that parathyroid hormone 1‐34 and anti‐sclerostin antibody attenuates radiation‐induced bone damage by accelerating DNA repair in osteoblasts. DNA damage responses are partially regulated by the ubiquitin proteasome pathway. In the current study, we examined whether proteasome inhibitors have similar bone‐protective effects against radiation damage. MG132 treatment greatly reduced radiation‐induced apoptosis in cultured osteoblastic cells. This survival effect was owing to accelerated DNA repair as revealed by γH2AX foci and comet assays and to the up‐regulation of Ku70 and DNA‐dependent protein kinase, catalytic subunit, essential DNA repair proteins in the nonhomologous end‐ joining pathway. Administration of bortezomib (Bzb) reversed the loss of trabecular bone structure and strength in mice at 4 wk after focal radiation. Histomorphometry revealed that Bzb significantly increased the number of osteoblasts and activity in the irradiated area and suppressed the number and activity of osteoclasts, regardless of irradiation. Two weeks of Bzb treatment accelerated DNA repair in bone‐lining osteoblasts and thus promoted their survival. Meanwhile, it also inhibited bone marrow adiposity. Taken together, we demonstrate a novel role of proteasome inhibitors in treating radiation‐induced osteoporosis.—Chandra, A., Wang, L., Young, T., Zhong, L., Tseng, W.‐J., Levine, M. A., Cengel, K., Liu, X. S., Zhang, Y., Pignolo, R. J., Qin, L. Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis. FASEB J. 32, 52‐62 (2018). www.fasebj.org
Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP)
Pignolo, Robert J. , Mukaddam, Mona Al , Shore, Eileen M. , Kaplan, Frederick S.

Mayo Clinic

Expert Opinion on Orphan Drugs | March 17, 2017 | Volume: 5 | Issue: 4 | Pages: 291-294

10.1080/21678707.2017.1304211 | PMID 29177121 Get It

Identification of Senescent Cells in the Bone Microenvironment
Fraser, Daniel G., Wang, Haitao , Jaehn, Katharina, Ogrodnik, Mikołaj , Weivoda, Megan , Tchkonia, Tamar , LeBrasseur, Nathan K. , Kirkland, James L. , Pignolo, Robert J. , Khosla, Sundeep , Wang, Haitao , Farr, Joshua N. , Ogrodnik, Mikolaj B, Weivoda, Megan M, Drake, Matthew T. , Tchkonia, Tamara, Monroe, David G. , Bonewald, Lynda F. , Khosla, Sundeep , Tchkonia, T , LeBrasseur, Nathan K , Wang, Haitao

Mayo Clinic

Journal of Bone and Mineral Research | June 24, 2016 | Volume: 31 | Issue: 11 | Pages: 1920-1929

10.1002/jbmr.2892 | PMID 27341653 Get It

ABSTRACT Cellular senescence is a fundamental mechanism by which cells remain metabolically active yet cease dividing and undergo distinct phenotypic alterations, including upregulation of p16Ink4a, profound secretome changes, telomere shortening, and decondensation of pericentromeric satellite DNA. Because senescent cells accumulate in multiple tissues with aging, these cells and the dysfunctional factors they secrete, termed the senescence-associated secretory phenotype (SASP), are increasingly recognized as promising therapeutic targets to prevent age-related degenerative pathologies, including osteoporosis. However, the cell type(s) within the bone microenvironment that undergoes senescence with aging in vivo has remained poorly understood, largely because previous studies have focused on senescence in cultured cells. Thus in young (age 6 months) and old (age 24 months) mice, we measured senescence and SASP markers in vivo in highly enriched cell populations, all rapidly isolated from bone/marrow without in vitro culture. In both females and males, p16Ink4a expression by real-time quantitative polymerase chain reaction (rt-qPCR) was significantly higher with aging in B cells, T cells, myeloid cells, osteoblast progenitors, osteoblasts, and osteocytes. Further, in vivo quantification of senescence-associated distension of satellites (SADS), ie, large-scale unraveling of pericentromeric satellite DNA, revealed significantly more senescent osteocytes in old compared with young bone cortices (11% versus 2%, p < 0.001). In addition, primary osteocytes from old mice had sixfold more (p < 0.001) telomere dysfunction-induced foci (TIFs) than osteocytes from young mice. Corresponding with the age-associated accumulation of senescent osteocytes was significantly higher expression of multiple SASP markers in osteocytes from old versus young mice, several of which also showed dramatic age-associated upregulation in myeloid cells. These data show that with aging, a subset of cells of various lineages within the bone microenvironment become senescent, although senescent myeloid cells and senescent osteocytes predominantly develop the SASP. Given the critical roles of osteocytes in orchestrating bone remodeling, our findings suggest that senescent osteocytes and their SASP may contribute to age-related bone loss. © 2016 American Society for Bone and Mineral Research
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, Robert A. , Fuleihan, Ghada El‐Hajj , Bauer, Douglas C. , Camacho, Pauline M., Clines, Gregory A. , Edwards, Beatrice J. , Favus, Murray J., Greenspan, Susan L., McKinney, Ross E. , Pignolo, Robert J. , Sellmeyer, Deborah E. , Clarke, Bart L, Drake, Matthew T. , Clarke, B.L. , Compston, Juliet , Bauer, Douglas C , El-Hajj Fuleihan, Ghada

Mayo Clinic

Journal of Bone and Mineral Research | September 9, 2015 | Volume: 31 | Issue: 1 | Pages: 16-35

10.1002/jbmr.2708 | PMID 26350171 Get It

ABSTRACT Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip T-score, between –2 and –2.5 in FLEX and below –2.5 in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip T-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.